目的:评估左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果,为我省急性心力衰竭患者治疗方案的合理选用提供参考。方法:根据全球SURVIVE临床试验数据,结合目前我省医疗及消费水平,采用成本-效果分析法分别对左西孟旦与多巴酚丁胺治疗急性心力衰竭的成本-效果及结果敏感度进行分析。结果:对于急性心力衰竭患者,短期(5 d)给予左西孟旦治疗的人均总成本为10 490.00元,多巴酚丁胺为6 637.18元。成本-效果分析及敏感度试验结果均表明,我省人均国内生产总值(GDP)<左西孟旦相较于多巴酚丁胺的增量成本-效果比<我省3倍GDP。结论:在我省目前的经济水平下,对于急性心力衰竭患者,采用左西孟旦的治疗方案较传统药物具有成本-效果优势。 OBJECTIVE: To evaluate the cost-effectiveness of levosimendan and dobutamine in the treatment of acute heart failure and to provide a reference for the rational selection of treatment regimens in patients with acute heart failure in our province. Methods: According to the global SURVIVE clinical trial data, combined with the current level of medical care and consumption in our province, the cost-effectiveness analysis method was used to analyze the cost-effectiveness and outcome sensitivity of levosimendan and dobutamine in the treatment of acute heart failure . RESULTS: For patients with acute heart failure, the total per capita cost of levvosim Chinese was $ 10,490.00 for short-term (5 days) treatment and $ 6,637.18 for dobutamine. Cost-effectiveness analysis and sensitivity test results show that the per capita GDP in our province